SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following impressive vehicle delivery numbers for December and Q4, surpassing expectations and fueling community excitement about its substantial year-over-year growth and nearing a million cumulative deliveries. The stock's undervaluation is a key talking point, with many anticipating future profitability bolstered by extended EV subsidies and the unique battery swap infrastructure, despite ongoing debates about market manipulation.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending with mixed community sentiment as the new year unfolds, fueled by widespread speculation regarding its immediate price action. Enthusiasts are vocal about their hopes for a significant rally, anticipating fresh buying interest as year-end tax adjustments conclude. The ongoing conversation reflects both strong community loyalty and debates surrounding its long-term trajectory as a prominent meme coin.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending due to significant community discussion surrounding recent share dilution for executive compensation, leading to frustration over persistent underperformance despite its substantial Bitcoin holdings. Investors are actively debating the company's valuation, with some seeing deep undervaluation due to unpriced energy infrastructure and an AI/HPC pivot, while others express concerns about management and potential further downside amidst heavy short interest.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending with massive volume and significant price action following news of a strategic manufacturing partnership to scale production of its fingerprinting drug screening reader. While many in the community are bullish on its low float, anticipating a short squeeze and further gains, strong concerns are rapidly emerging regarding a recently announced private placement at a lower price, sparking fears of significant dilution.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending with a notable price surge, leading to a highly divided community conversation. Many are expressing frustration, calling it a "scam" due to perceived manipulation and past volatility, while others remain optimistic, citing its real-world utility through Flexa partnerships and potential for future institutional adoption, especially with upcoming regulatory clarity.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending amid significant community discussion around strategic moves to enhance its utility and institutional presence, particularly with the launch of Europe's first ETP. The community also eagerly anticipates a substantial token burn as it approaches a key holder milestone, fueling mixed sentiment and speculation about a potential rally within the Solana ecosystem.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO is trending due to its "Infinite Money Glitch" protocol, which consistently distributes passive Solana rewards to holders, cultivating a highly dedicated and resilient community. Despite recent chart movements, a strong bullish sentiment persists, fueled by anticipation for upcoming LP rewards, the imminent launch of real-time audit technology, and its ambitious aim to integrate with major gaming economies.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is actively trending due to its Q3 earnings, significant advancements in AI and humanoid robotics, and strong pre-order demand for its new X9 EREV hybrid. Community sentiment is divided, with many citing undervaluation and global expansion as key bullish drivers, while others point to frustrating price drops and perceived market manipulation in the Chinese EV sector. Attention remains on upcoming delivery figures and the company's path to sustained profitability amidst new EV incentives.

Pump.fun

PUMP.FUN is actively trending amid ongoing legal challenges, including a major lawsuit with whistleblower revelations and a former developer's sentencing, fueling speculation across the community. Many are debating whether current price action represents a "bear trap" or indicates deeper issues, even as affiliated meme projects within the Solana ecosystem rally for continued growth.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is seeing significant discussion following an unexpected Q3 loss and a cautious Q4 delivery outlook, which has fueled mixed sentiment within the investor community. Despite these challenges, the launch of the company's new AI-powered smart glasses is generating buzz, while renewed government subsidies for electric vehicles are providing a sector-wide tailwind, influencing views on Li Auto's new i6 SUV and broader market position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for...

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2025

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two...

Kezar Life Sciences (KZR) shares rallied 47% on Friday afternoon despite analyst downgrades and price target cuts.Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to ‘Hold’ from ‘Buy’ with a price target of $7, down from $18. Meanwhile, William Blair analyst Matthew Phipps downgraded Kezar Life Sciences to ‘Market Perform’ from ‘Outperform’ without a price target. Wells Fargo kept its ‘Equal Weight’ rating on the shares but slashed the price target to $5 from $7.Kezar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-announces-regulatory-update-zetomipzomib">announced</a> on Thursday that it has initiated a process to explore strategic alternatives focused on maximizing shareholder value after being unable to align with the U.S. Food and Drug Administration on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis (AIH). Autoimmune hepatitis is a rare, chronic disease that predominantly affects women and, if left untreated, can lead to cirrhosis, liver failure, and hepatocellular carcinoma.However, the FDA Division of Hepatology and Nutrition cancelled a Type C meeting that was previously scheduled with Kezar in the fourth quarter to discuss a proposed study in AIH, the company said.Earlier this year, Kezar reported positive safety and efficacy data from a clinical trial in patients with refractory or relapsed AIH. However, the regulator requested that Kezar conduct a stand-alone study to define the pharmacokinetics of Zetomipzomib in subjects with significant hepatic impairment before the initiation of another clinical trial in AIH.This study would delay future trials of Zetomipzomib in AIH by approximately two years, the company said, while adding that the requirements put forth by the FDA would also hinder patient enrollment and participation.“While we remain excited about the potential of Zetomipzomib to be the first approved agent in AIH, we lack the resources to extend the development timeline,” CEO Chris Kirk said.The company also said it would be implementing a restructuring plan, including layoffs and other cash conservation measures, as part of the strategic alternative evaluation.William Blair said on Friday that it is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar's current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.Wells, however, thinks there could be upside if they return cash to shareholders or in a reverse merger scenario.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZR">KZR stock</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_12_46_33_PM_png_393ca210c9.webp" alt="KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that $6.50 to $7 would be a good range for the stock.<stembedurl>https://stocktwits.com/StockBoyAri/message/632736011</stembedurl>Another user expressed doubts over the rally.<stembedurl>https://stocktwits.com/CMCanalyst/message/632743196</stembedurl>KZR stock is down by 9% this year and by about 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artiva-biotherapeutics-gets-price-target-hike-from-wedbush/ch6sW9tR38A">Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.

Equity

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.


Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today...

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy

Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 19, 2015 and is headquartered in South San Francisco, CA.

Current Price	$6.29
Prev Close	$6.26
Open	$6.29
Dividend Yield	0.00%
50-Day Moving Average	$6.22
Beta	1.05
Avg. Volume	42,902.11
PE Ratio	-0.74

52-Week High	$6.93
52-Week Low	$3.53
Market Capitalization	$45.84M
EPS (Annual)	-$11.49
Price to Book	0.56
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KZR
Kezar Life Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KZR News

KZRKezar Life Sciences Inc